Get your full text copy in PDF
Long-Bin Jeng, Ashok Thorat, Horng-Ren Yang, Chun-Chieh Yeh, Te-Hung Chen, Chia-Hao Hsu, Shih-Chao Hsu, Kin-Shing Poon, Ping-Chung Li, Hsueh-Chou Lai, Wen-Pang Su, Cheng-Yuan Peng
(Organ Transplantation Center, China Medical University Hospital, Taichung, Taiwan)
Ann Transplant 2015; 20:103-111
Due to high prevalence of hepatitis B virus (HBV) infection in Taiwan, liver grafts from donors positive for hepatitis B surface antigen (HBsAg) without progressive disease can be effective alternative source of donor organs. This study aims to prove the safety of living donor liver transplantation (LDLT) using HBsAg-positive liver grafts and its long-term outcome.
Material and Methods: We studied 14 consecutive LDLT recipients that received HBsAg-positive grafts from November 2009 to December 2013 for various indications. All donors were chronic HBsAg carriers with normal liver function tests. Median follow-up was 46 months (range, 35–59).
Results: All the donors and recipients recovered well post-transplant with no reactivation of HBV to date. Two of the recipients died due to extra-hepatic recurrence of HCC. At median follow-up of 46 months, 4-year cumulative survival of recipients was 77.38%.
Conclusions: In endemic areas, HBsAg-positive donor organs can clearly be used effectively under viral immunoprophylaxis. HBV disease reactivation does not appear to be a threat even with hepatitis B immunoglobulin (HBIG)-free antiviral monoprophylaxis regimen. This study thus proves the safety and feasibility of the option of using HBsAg-positive grafts in high-prevalence areas.
Keywords: End stage liver disease, Liver Failure, Acute, Liver Neoplasms